Intravitreal application of epidermal growth factor in non-exudative age-related macular degeneration

CONCLUSIONS: Except for one eye with temporary, self-resolving cystoid macular oedema, single and repeated intravitreal applications of EGF (0.75 µg) in patients with GA did not lead to intraocular inflammations or any observed intraocular side effect.TRIAL REGISTRATION NUMBER: ISRCTN12733334.PMID:34261661 | DOI:10.1136/bjophthalmol-2021-319582
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Source Type: research